Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome.
Satoshi YamashitaAtsushi SakamotoSatoshi ShojiYoshitaka KawaguchiYasushi WakabayashiMasaki MatsunagaKiyohisa SuguroYuji MatsumotoHiroyuki TakaseTomoya OnoderaKei TawaraharaMasahiro MutoYasutaka ShirasakiHideki KatohMakoto SanoKenichiro SuwaYoshihisa NaruseHayato OhtaniMasao SaotomeTsuyoshi UrushidaShun KohsakaEisaku OkadaYuichiro MaekawaPublished in: Journal of cardiovascular development and disease (2023)
In ACS patients who underwent PCI, short-term PCSK9 antibody therapy with conventional LLT was feasible in this pilot clinical trial. Long-term follow-up in a larger scale clinical trial is warranted.
Keyphrases
- acute coronary syndrome
- clinical trial
- percutaneous coronary intervention
- antiplatelet therapy
- end stage renal disease
- study protocol
- chronic kidney disease
- ejection fraction
- open label
- prognostic factors
- phase iii
- phase ii
- peritoneal dialysis
- patient reported outcomes
- st elevation myocardial infarction
- randomized controlled trial
- mesenchymal stem cells
- fatty acid
- cell therapy
- st segment elevation myocardial infarction
- coronary artery bypass grafting
- smoking cessation